Skip to main content
Erschienen in: Hepatology International 1/2013

01.03.2013 | Original Article

Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy

verfasst von: Chia-Yang Hsu, Yun-Hsuan Lee, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo, Shou-Dong Lee

Erschienen in: Hepatology International | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Ascites may develop in patients with hepatocellular carcinoma (HCC) with coexisting liver cirrhosis. Few studies had specifically evaluated the role of ascites in HCC. This study investigated its prevalence, associated factors, prognostic impact, and staging strategy in a large HCC patient cohort.

Patients and methods

A total of 2,203 HCC patients were analyzed. The grading of ascites was according to the European Association for the Study of Liver. The prognostic ability of the Cancer of the liver Italian Program (CLIP), Barcelona Clinic Liver Cancer, Japan Integrated Scoring system, and Taipei Integrated Scoring system in HCC patients with ascites was compared using the Akaike information criterion (AIC).

Results

Ascites was present in 498 (23%) patients at diagnosis. Grades 1, 2, and 3 ascites were found in 13, 5, and 5% of the patients, respectively. The severity of ascites significantly correlated with hyperbilirubinemia, hypoalbuminemia, hyponatremia, prothrombin time (PT) prolongation, and renal insufficiency (all p < 0.001). Large tumor burden and more frequent vascular invasion were often observed in patients with more severe ascites (both p < 0.001). In the Cox proportional hazard model, ascites was identified as an independent prognostic predictor with 80–94% increased risk of mortality (p < 0.001). Among HCC patients with ascites, the CLIP system had the lowest AIC value.

Conclusions

Ascites is often seen in HCC patients and is associated with both tumoral and cirrhosis factors and decreased long-term survival. The CLIP staging system is a more feasible prognostic model for HCC patients with ascites. The optimal treatment strategy for these patients remains to be investigated.
Literatur
1.
Zurück zum Zitat Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–474PubMedCrossRef Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–474PubMedCrossRef
2.
Zurück zum Zitat El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823PubMed El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823PubMed
3.
Zurück zum Zitat Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–538PubMedCrossRef Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–538PubMedCrossRef
4.
Zurück zum Zitat Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vi1–vi12PubMedCrossRef Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vi1–vi12PubMedCrossRef
6.
Zurück zum Zitat Hsu CY, Huang YH, Su CW, et al. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010;30:77–84PubMedCrossRef Hsu CY, Huang YH, Su CW, et al. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010;30:77–84PubMedCrossRef
7.
Zurück zum Zitat Huo TI, Lui WY, Wu JC, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg 2004;28:258–262PubMedCrossRef Huo TI, Lui WY, Wu JC, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg 2004;28:258–262PubMedCrossRef
8.
Zurück zum Zitat The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840–845CrossRef The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840–845CrossRef
9.
10.
Zurück zum Zitat Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396–1405PubMedCrossRef Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396–1405PubMedCrossRef
11.
Zurück zum Zitat Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108–117PubMedCrossRef Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108–117PubMedCrossRef
12.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430PubMedCrossRef
13.
Zurück zum Zitat Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988;8:12–25PubMedCrossRef Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988;8:12–25PubMedCrossRef
14.
Zurück zum Zitat European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397–417CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397–417CrossRef
15.
Zurück zum Zitat Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(Suppl 1):141–156PubMedCrossRef Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(Suppl 1):141–156PubMedCrossRef
16.
Zurück zum Zitat Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726–748PubMedCrossRef Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726–748PubMedCrossRef
17.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655PubMedCrossRef
18.
Zurück zum Zitat Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004;10:301–319PubMedCrossRef Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004;10:301–319PubMedCrossRef
19.
Zurück zum Zitat Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321–345PubMedCrossRef Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321–345PubMedCrossRef
20.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699PubMedCrossRef Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699PubMedCrossRef
21.
Zurück zum Zitat Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006;107:141–148PubMedCrossRef Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006;107:141–148PubMedCrossRef
22.
Zurück zum Zitat Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006;101:975–982PubMedCrossRef Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006;101:975–982PubMedCrossRef
23.
Zurück zum Zitat Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006–3014PubMedCrossRef Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006–3014PubMedCrossRef
24.
Zurück zum Zitat Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965–980PubMedCrossRef Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965–980PubMedCrossRef
25.
Zurück zum Zitat Feinstein AR. Clinical biostatistics. XVI. The process of prognostic stratification. Clin Pharmacol Ther 1972;13:609–624PubMed Feinstein AR. Clinical biostatistics. XVI. The process of prognostic stratification. Clin Pharmacol Ther 1972;13:609–624PubMed
26.
Zurück zum Zitat Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:64–70PubMedCrossRef Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:64–70PubMedCrossRef
27.
Zurück zum Zitat Casado M, Bosch J, García-Pagán JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296–1303PubMedCrossRef Casado M, Bosch J, García-Pagán JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296–1303PubMedCrossRef
28.
Zurück zum Zitat Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716–1724PubMedCrossRef Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716–1724PubMedCrossRef
29.
Zurück zum Zitat Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652–1660PubMedCrossRef Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652–1660PubMedCrossRef
30.
Zurück zum Zitat Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018–1026PubMedCrossRef Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018–1026PubMedCrossRef
31.
Zurück zum Zitat Hsu CY, Huang YH, Su CW, et al. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol 2010;44:e171–e177PubMed Hsu CY, Huang YH, Su CW, et al. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol 2010;44:e171–e177PubMed
32.
Zurück zum Zitat Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302–308PubMedCrossRef Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302–308PubMedCrossRef
33.
Zurück zum Zitat Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146PubMedCrossRef Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146PubMedCrossRef
34.
Zurück zum Zitat Huo TI, Hsu CY, Huang YH, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010;30:198–207PubMedCrossRef Huo TI, Hsu CY, Huang YH, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010;30:198–207PubMedCrossRef
35.
Zurück zum Zitat Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J Chin Med Assoc 2005;68:155–159PubMedCrossRef Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J Chin Med Assoc 2005;68:155–159PubMedCrossRef
36.
Zurück zum Zitat Hsin IF, Hsu CY, Huang HC, et al. Incidence, risk factors and prognostic impact of liver failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. J Clin Gastroenterol 2011;45:556–562PubMedCrossRef Hsin IF, Hsu CY, Huang HC, et al. Incidence, risk factors and prognostic impact of liver failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. J Clin Gastroenterol 2011;45:556–562PubMedCrossRef
37.
Zurück zum Zitat Tsai YJ, Hsu CY, Huang YH, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975–984CrossRef Tsai YJ, Hsu CY, Huang YH, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975–984CrossRef
38.
Zurück zum Zitat Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274–1283PubMedCrossRef Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274–1283PubMedCrossRef
39.
Zurück zum Zitat Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008;113:2742–2751PubMedCrossRef Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008;113:2742–2751PubMedCrossRef
Metadaten
Titel
Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy
verfasst von
Chia-Yang Hsu
Yun-Hsuan Lee
Yi-Hsiang Huang
Cheng-Yuan Hsia
Chien-Wei Su
Han-Chieh Lin
Rheun-Chuan Lee
Yi-You Chiou
Fa-Yauh Lee
Teh-Ia Huo
Shou-Dong Lee
Publikationsdatum
01.03.2013
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 1/2013
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9338-z

Weitere Artikel der Ausgabe 1/2013

Hepatology International 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.